Compare · IRIX vs PRKS
IRIX vs PRKS
Side-by-side comparison of IRIDEX Corporation (IRIX) and United Parks & Resorts Inc. (PRKS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IRIX and PRKS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- PRKS is the larger of the two at $2.16B, about 132.6x IRIX ($16.3M).
- Over the past year, IRIX is down 25.1% and PRKS is down 7.4% - PRKS leads by 17.7 points.
- PRKS has been more active in the news (11 items in the past 4 weeks vs 4 for IRIX).
- PRKS has more recent analyst coverage (8 ratings vs 0 for IRIX).
- Company
- IRIDEX Corporation
- United Parks & Resorts Inc.
- Price
- $0.95-9.41%
- $45.04-4.17%
- Market cap
- $16.3M
- $2.16B
- 1M return
- -20.07%
- -2.01%
- 1Y return
- -25.10%
- -7.39%
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- NYSE
- IPO
- 1996
- 2013
- News (4w)
- 4
- 11
- Recent ratings
- 0
- 8
IRIDEX Corporation
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.
Latest IRIX
- SEC Form 8-K filed by IRIDEX Corporation
- President and CEO Mercer Patrick was granted 100,000 shares, increasing direct ownership by 27% to 468,784 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R was granted 30,000 shares, increasing direct ownership by 23% to 163,284 units (SEC Form 4)
- Large owner Novel Inspiration International Co., Ltd. acquired 111,997 shares (SEC Form 4)
- IRIDEX Corporation filed SEC Form 8-K: Other Events
- Chief Financial Officer Dizon Romeo R covered exercise/tax liability with 2,691 shares, decreasing direct ownership by 2% to 133,284 units (SEC Form 4)
- President and CEO Mercer Patrick covered exercise/tax liability with 3,990 shares, decreasing direct ownership by 1% to 368,784 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $1,110 worth of shares (975 units at $1.14), increasing direct ownership by 0.72% to 135,975 units (SEC Form 4)
- Chief Financial Officer Dizon Romeo R bought $1,909 worth of shares (1,675 units at $1.14), increasing direct ownership by 1% to 135,000 units (SEC Form 4)
- Iridex to Present at the Planet MicroCap Las Vegas 2026 Conference
Latest PRKS
- UNITED PARKS & RESORTS INC. ANNOUNCES SECOND QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION
- Northcoast initiated coverage on United Parks & Resorts Inc.
- Large owner Hill Path Capital Partners Co-Investment S Lp was granted 1,821 shares (SEC Form 4)
- Large owner Hill Path Capital Partners Lp was granted 1,821 shares (SEC Form 4)
- Director Chambers James P. was granted 1,098 shares, increasing direct ownership by 2% to 65,558 units (SEC Form 4)
- Director Gray William was granted 1,258 shares, increasing direct ownership by 2% to 76,721 units (SEC Form 4)
- Director Hartnett Timothy was granted 1,821 shares, increasing direct ownership by 2% to 81,378 units (SEC Form 4)
- Director Lipman Nathaniel was granted 207 shares, increasing direct ownership by 1% to 20,316 units (SEC Form 4)
- Director Schaefer Kimberly was granted 415 shares, increasing direct ownership by 0.98% to 42,740 units (SEC Form 4)
- Director Narang Neha Jogani was granted 830 shares, increasing direct ownership by 1% to 57,376 units (SEC Form 4)